Multiple sclerosis and related disorders · 2021
Clinical perspective on clinical outcome assessments in neurosarcoidosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moss Brandon P, Miller Deborah M, Culver Daniel A
Аннотация
BACKGROUND: There are no validated clinical outcome assessments (COAs) used in neurosarcoidosis.
OBJECTIVE: We surveyed clinicians who treat patients with neurosarcoidosis to determine: 1) current approaches to assessment of neurologic impairment, and 2) clinicians' needs regarding future COA development.
METHODS: Physician contacts from the Foundation for Sarcoidosis Research and Neurosarcoidosis Consortium Group were sent an online survey.
RESULTS: For 43/143 responders, COAs were used in a minority of settings. Apart from time for administration, the biggest barriers to implementation were lack of validated, disease-specific measures.
CONCLUSIONS: Lack of validated, disease-specific measures is a barrier to monitoring neurological impairment in neurosarcoidosis.
OBJECTIVE: We surveyed clinicians who treat patients with neurosarcoidosis to determine: 1) current approaches to assessment of neurologic impairment, and 2) clinicians' needs regarding future COA development.
METHODS: Physician contacts from the Foundation for Sarcoidosis Research and Neurosarcoidosis Consortium Group were sent an online survey.
RESULTS: For 43/143 responders, COAs were used in a minority of settings. Apart from time for administration, the biggest barriers to implementation were lack of validated, disease-specific measures.
CONCLUSIONS: Lack of validated, disease-specific measures is a barrier to monitoring neurological impairment in neurosarcoidosis.